Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf to Advagraf
NCT01294020Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- May 2011
- Primary completion
- Nov 2025
- Modality
- RNA-Targeting Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of tacrolimus in Allograft Rejection (AR), sponsored by Astellas Pharma. Started May 2011; status: completed.
02
Drugs
tacrolimus
03
Conditions
Allograft Rejection (AR)
Beyond the preview
Go deeper on NCT01294020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01294020.